The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Transcatheter aortic valve implantation of a novel system for severe pure native aortic regurgitation in a patient with ascending aorta aneurysm
Hendrik Wienemann1, MD; Hesham Elzomor2, MD; Elmar Kuhn3, MD; Jan-Malte Sinning4, MD; Stephan Baldus1, MD; Patrick W. Serruys2, MD, PhD; Matti Adam1, MD
1. Clinic III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; 2. Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; 3. Department of Cardiothoracic Surgery, Faculty of Medicine and University Hospital Cologne, Germany; 4. Department of Cardiology, St Vinzenz-Hospital, Cologne, Germany
According to the Euro Heart Survey II on valvular heart disease1, 7.4% of patients with single left-sided valve heart disease have native aortic regurgitation (AR). AR is often accompanied by aneurysm or dilatation of the ascending aorta. In these conditions transcatheter aortic valve implantation (TAVI) remains a therapeutic challenge, since the absence of aortic valve calcification can result in inadequate anchoring of the stent frame, which could therefore result in subsequent valve embolisation or relevant paravalvular regurgitation2.
The JenaValve Trilogy (JenaValve) is a self-expanding valve with a supra-annular porcine valve sutured on a nitinol stent. In May 2021, it became ...